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Since mid-1990s, the field of cancer immunotherapy has seen steady growth and 
selected immunotherapies are now a routine and preferred therapeutic option of certain 
malignancies. Both active and passive cancer immunotherapies exploit the fact that 
tumor cells express specific antigens on the cell surface, thereby mounting an immune 
response specifically against malignant cells. It is well established that cancer cells 
typically lose surface antigens following natural or therapy-induced selective pressure 
and these antigen-loss variants are often the population that causes therapy-resistant 
relapse. CD19 and CD20 antigen loss in acute lymphocytic leukemia and chronic lym-
phocytic leukemia, respectively, and lineage switching in leukemia associated with mixed 
lineage leukemia (MLL) gene rearrangements are well-documented evidences in this 
regard. Although increasing number of novel immunotherapies are being developed, 
majority of these do not address the control of antigen loss variants. Here, we review 
the occurrence of antigen loss variants in leukemia and discuss the therapeutic strate-
gies to tackle the same. We also present an approach of dual-targeting immunoligand 
effectively retargeting NK cells against antigen loss variants in MLL-associated leukemia. 
Novel immunotherapies simultaneously targeting more than one tumor antigen certainly 
hold promise to completely eradicate tumor and prevent therapy-resistant relapses.
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iNtrODUctiON
In what is known as cancer immunoediting, the immune system not only tries to eradicate the evolv-
ing tumor but, in doing so, also shapes the immunogenicity of the tumor that may escape the immune 
control (1). Ultimately, the tumor cells that progress despite the immunosurveillance consist of one 
or more clones with lower visibility and/or higher resistance to the immune cells (1). For example, 
tumors often decrease the expression of components required for antigen presentation (MHC) and/
or T cell activation (costimulatory molecules) as well as ligands for the NK cell-activating recep-
tors in order to hide from the T and NK cells, respectively (1–4). Alternatively, tumor cells express 
ligands, which, upon binding to the respective checkpoint receptors such as CTLA-4 and PD-1 on T 
cells and KIR and CD94/NKG2A on NK cells, suppress their effector functions (5–9). The following 
sections review the current targeted therapies and the evidences of relapses associated with antigen 
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loss variants in leukemia. Several therapeutic approaches includ-
ing a dual-targeting immunoligand to manage this challenging 
clinical scenario are discussed.
tArGeteD iMMUNOtHerAPies—
cUrreNt stAtUs iN LeUKeMiA
Acute leukemia represents an uncontrolled proliferation of the 
immature immune precursor cells and are further classified based 
on the lineage of the affected immune cell. Acute lymphocytic 
leukemia (ALL) affects the cells from the lymphoid lineage in 
contrast to the leukemia of myeloid cells, collectively known as 
acute myeloid leukemia (AML) (10). Both lymphoid and myeloid 
leukemia exploit the abovementioned and several other immune 
evasive strategies [reviewed in Ref. (6)]. However, the fact that 
tumor cells have to evade the immune system in order to be clini-
cally relevant disease also supports the idea that immune system, 
when properly activated, can fight the cancer.
Over the last three decades, the cancer immunotherapy field 
has seen much progress and most of its success can be attributed 
to the targeted therapies against leukemia (11). The most prom-
ising immunotherapeutic options for leukemia include targeted 
approaches such as chimeric antigen receptor (CAR) modified 
T cells (CAR-T cells) and antibody-based therapies that activate 
T and NK cells (11). Within the CAR construct, extracellular 
antibody-derived scFv confers the antigen specificity, while the 
intracellular signaling domains (from T cell receptor and costim-
ulatory molecule) provide the activation signal to the engineered 
T cells (12). Various CAR-T cells have entered the clinical studies 
for leukemia and the most advanced CAR is against CD19, which 
is being tested for ALL (13, 14). Blinatumomab, a bispecific T 
cell engager against CD19 and CD3 that recently got the FDA 
approval for the treatment of ALL, is an antibody-based molecule 
that also activates T cells, albeit via CD3, against the CD19-bearing 
target cells (15). NK cells, like T cells, have equally contributed to 
the clinical success of cancer immunotherapy against leukemia. 
For example, NK cells serve as an important effector population 
in chronic lymphocytic leukemia (CLL) patients who mediate 
antibody-dependent cell-mediated cytotoxicity through FcγRIIIa 
(CD16a) receptor engagement by the FDA-approved anti-CD20 
antibodies (rituximab, obinutuzumab, and ofatumumab), anti-
CD52 antibody alemtuzumab, and other promising anti-CD19 
antibodies (MEDI-551 and XmAb5574) that are currently in 
clinical trials (16). In addition to the conventional antibodies, 
there are numerous novel approaches currently in preclinical 
development that aim to harness NK cell activity against cancer 
[reviewed in Ref. (8)].
Although many of the targeted immunotherapies have 
produced unprecedented responses in leukemia, especially in 
chemorefractory patients, the complete remissions observed 
following such therapies are not long-lasting and a large variety 
of leukemia cases are presented with relapses that are aggressive 
and difficult to manage. This dismal scenario emphasizes the 
intratumoral heterogeneity that is driven by the intrinsic factors 
such as accumulation of genetic and epigenetic mutations during 
tumor progression and extrinsic factors imposed by therapeutic 
pressure and tumor microenvironment (17, 18).
OccUrreNce OF ANtiGeN LOss 
vAriANts iN LeUKeMiA
Around 30% of acute leukemia patients experience a relapse with 
occasional co-presentation of a phenomenon known as “lineage 
switch.” Lineage switching occurs when acute leukemia that was 
initially classified as lymphoid or myeloid subtype according 
to the standard French–American–British guidelines shows 
opposite lineage when relapsed (10, 19). This phenomenon is 
often associated with poor prognosis and therapy resistance 
regardless of whether it emerged due to the lineage conversion 
of the original malignant clone or the selective outgrowth of a 
new leukemic clone (10). Out of the two possibilities, lymphoid 
to myeloid lineage switch is more frequently observed with more 
cases reported in children and often associated with the mixed 
lineage leukemia (MLL) gene rearrangements on chromosome 
11q23 (20, 21).
Most cases of lineage switch have been reported in patients who 
had undergone some sort of targeted therapy. CD19-targeting 
immunotherapies including a bispecific antibody blinatumomab 
and CAR-expressing T cells have been very effective in chem-
orefractory B cell ALL. Anti-CD19/CD3 antibody blinatumomab 
redirects endogenous T cells in patients (15), while anti-CD19 
CAR T cells are genetically engineered to be specifically activated 
against CD19 expressing target cells when infused in patients 
(22). Despite exceptional responses associated with these targeted 
therapies, some patients relapse and in many cases loss of CD19 
antigen is reported. Duffner et al. reported a patient who was diag-
nosed with B-ALL associated with MLL-gene rearrangements but 
with no evidence of mixed lineage phenotype. Although blinatu-
momab therapy led to the complete disappearance of leukemic 
B cells, the patient relapsed with a more aggressive monocytic 
AML, which was negative for typical lymphoid markers such as 
CD19 (20). Similarly, CD19-specific CAR-T cell therapy could 
achieve complete response in all seven MLL-rearranged B-ALL 
patients. However, two of the seven patients relapsed with clon-
ally related AML with no expression of B lymphoid antigens (21). 
Interestingly, both patients who showed lineage switch also had 
the presentation of cytokine release syndrome (21). Interleukin-6 
(IL6), a key mediator of cytokine release syndrome, has also been 
shown to induce lymphoid to myeloid dedifferentiation in vitro 
(23) and in vivo (24). Although this is an indication of myeloid 
dedifferentiation of the original lymphoid blasts as an indirect 
effect of CAR-T cell therapy, it is also possible that myeloid clone 
is already present along with the lymphoid blasts, albeit below 
detection level, and is selected following the lymphoid-directed 
therapy. Ruella et al. recently described the presence of a small 
CD19-negative population in B-ALL patients before the admin-
istration of anti-CD19 CAR-T cell therapy (CTL019). Although 
there were no cases involving lineage switch, patients relapsed 
with CD19-negative B cell tumor following the CAR-T cell therapy 
(CTL019) and, as proposed by the authors, was most likely due to 
the selective outgrowth of the original CD19-negative subclone 
(13, 25). Beyond targeted immunotherapies, the phenomenon of 
lineage switch has also been observed following chemotherapy. 
As reported by Park et al., four patients of childhood B cell lineage 
ALL were treated with chemotherapy and were later presented 
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with the relapse of clonally related AML (one patient) or a novel 
AML clone (three patients) (19).
While the link between treatment and lineage switching is 
not clear, the precise mechanism of antigen loss following mAb 
therapy is identified in several B cell malignancies. Rituximab, a 
chimeric antibody against CD20, has become a standard thera-
peutic option for various B cell (CD20+) malignancies including 
non-Hodgkin lymphoma (NHL), follicular lymphoma, diffuse 
large B cell lymphoma, and CLL (26, 27). The loss of CD20 
antigen following rituximab therapy has been observed for fol-
licular lymphoma (27), B cell NHL (28), and CLL (29). Two main 
mechanisms have been reported for CD20 loss from the CLL cells 
following rituximab (anti-CD20 mAb) treatment. While CD20 
internalization by malignant B cells plays a minor role, the major-
ity of CD20, along with the bound rituximab, is removed by the 
Fcγ receptor-expressing monocytes and macrophages in a pro-
cess called as trogocytosis or shaving (30–32). This does not only 
result in the rapid clearance of rituximab following the infusion 
but also leads to selection of CD20-negative CLL cells that are 
resistant to anti-CD20 therapy. Similarly, CD19 internalization 
is also reported by anti-CD19 antibody XmAb5574 in CLL (33). 
Interestingly, Jones et al. reported the loss of CD19 from the CLL 
cells during the shaving (trogocytosis) of anti-CD20 rituximab. 
It was shown that CD19 was also transferred from B cells to 
monocytes in Fc receptor-dependent manner (34). Moreover, 
antigen loss in CLL is not only associated with the mAb therapy, 
for example, decrease in the cell surface expression of CD20 is 
observed by an immune modulating agent lenalidomide (26) or 
following the long-term in  vitro coculture with mesenchymal 
stromal cells (29).
tHerAPeUtic strAteGies tO cOMBAt 
tHe ANtiGeN LOss vAriANts
As most tumor relapses involving antigen loss have been observed 
following antigen-specific therapies, one plausible solution is 
to use therapeutic approaches that are more general in their 
specificity and do not depend upon a particular tumor antigen. 
Immunotherapy with cytokine(s) such as IL2, IL12, and IL15 act 
via enhancing NK and T cell-mediated immune response against 
tumor (35). Although side effects associated with cytokines (e.g., 
IL2 and interferons) greatly limit their current use in the clinics, 
this approach still holds promise especially at lower doses and in 
combination with other anti-cancer therapies (35). Alternatively, 
checkpoint blockade involves blocking of the inhibitory receptors 
on immune cells to reverse the immune suppression by tumor 
cells (36, 37). Recent success in blocking of inhibitory receptors 
on T cells such as CTLA-4 and PD-1 by FDA-approved antibod-
ies (checkpoint inhibitors) has led to the development of novel 
checkpoint inhibitors blocking NK cell inhibitory receptors KIR 
(lirilumab, Innate Pharma) and CD94/NKG2A (IPH2201, Innate 
Pharma) (36–38). The advantage is that such immune-modulatory 
approaches aim to promote an overall antitumor environment 
and are predicted to be less susceptible to the limitations associ-
ated with tumor heterogeneity and antigen loss (39). However, 
treatment options with no specificity for tumor are less likely 
to be curative as mono-agents and are often associated with the 
systemic side effects as observed in the form of immune-related 
adverse events following the checkpoint blockade approach (40).
Another strategy is to broaden the specificity of the current 
targeted therapies that have already shown promise in the clin-
ics. CAR-T cells with dual specificities have been developed to 
improve T cell targeting of tumor cells even when one of the 
antigens is lost from the cell surface. A prototype CAR T cell with 
two distinct antigen-specific scFvs in tandem (TanCAR) retained 
T cell activity against antigen loss variants (41). The treatment 
of B-ALL patients enrolled in the pediatric CTL019 trial (the 
University of Pennsylvania/Children’s Hospital of Philadelphia) 
with CD19-specific CAR-T cells led to the outgrowth of CD19-
negative malignant clone, which retained the expression of an IL3 
receptor α chain (CD123) (25). Taking advantage of this, Ruella 
et al. developed CD19/CD123 CAR-T cells and proved its ability 
to completely eradicate the primary B-ALL blasts (CD19+CD123+ 
and CD19-CD123+) and to prevent the CD19 antigen loss relapse 
in an immunodeficient (NSG) mouse model (25). Despite 
the encouraging progress with the dual-specific CAR-T cell 
approach, major safety concerns typically associated with CAR-T 
cell therapy such as “on-target, off-tumor toxicity” and “cytokine 
release syndrome” would demand an equal attention (42).
Alternatively, NK cells, unlike T cells, express a diverse array 
of activating and inhibitory receptors to sense for the presence 
of stressed, virally infected or malignant cells. Moreover, there 
are multiple ligands for some of the activating receptors on NK 
cells (43). For example, the natural killer group 2 member D 
(NKG2D), an activating receptor on NK cells, can induce NK cell 
effector functions upon binding to any of the natural ligands such 
as UL16-binding proteins (ULBP1-6) and MHC-I-related chains 
(MICA/B) (43). This makes NK cells unlikely to succumb to the 
tumor heterogeneity and antigen loss provided that malignant 
cells remain visible to the NK cell scanning. However, the ligands 
for the NK cell-activating receptors, including NKG2D, are occa-
sionally lost from the surface of leukemic cells in order to evade 
NK cell immunity (2, 3, 44). Of note, as shown by the recent work 
of Deng et al., soluble MULT1, a murine NKG2D ligand, played 
an indirect role in promoting NK cell immunity suggesting that 
soluble ligands may be more than inhibitory for overall NK cell 
activity (45). Our group has developed a therapeutic strategy to 
resensitize leukemic cells for NKG2D-dependent NK cell attack. 
To this end, we have developed and tested several bi- and trispe-
cific recombinant immunoligands containing an NKG2D ligand 
ULBP2 fused to the various tumor antigen-specific scFvs (46–48). 
The idea is that these immunoligands will bind specifically to the 
tumor antigens and will coat the tumor cells with ULBP2 ligand. 
This will turn the otherwise NK cell-resistant tumor cells visible to 
NK cells for the attack. This was recently tested for the trispecific 
immunoligands (triplebodies) against CLL and MLL cells, which 
showed successful NK cell-mediated killing of leukemic cells in 
both, in vitro and in vivo settings (47).
The ability of a dual-targeting triplebody ULBP2-aCD19-
aCD33 to target antigen loss variants is showed in the present 
report. The term “dual-targeting triplebody” represents a trispe-
cific immunoligand targeting two distinct antigens such as CD19 
and CD33 in the case of ULBP2-aCD19-aCD33 against a B-cell 
precursor leukemic cell line BV173. The rational of this approach 
FiGUre 1 | Harnessing NK cells to control antigen loss variants: rational for the dual-targeting immunoligand approach. Emergence of antigen loss 
variants in most cases is seen following targeted therapy and can be associated with lineage switching (A), shaving or trogocytosis of antigen–antibody complexes 
from the tumor cells (B) or selective outgrowth of antigen-negative cells (c). NK cell activating dual targeting immunoligand (triplebody) consists of two scFvs against 
distinct antigens on tumor cells and a natural ligand to activate NK cells. As an example, ULBP2-aCD19-aCD33 (dual targeting triplebody) binds not only to the 
double antigen-positive (CD19+CD33+) target cells but also to the antigen loss variants. ULBP2, now coated on the target cells, activates NK cell effector functions 
via NKG2D receptor resulting in the killing of tumor cells by perforin and granzymes and secretion of IFNγ and TNFα. For simplicity, cross-linking is only shown 
between CD19+CD33+ target cells and NK cell; however, identical NK cell targeting is possible in response to antigen loss variants.
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is that ULBP2-aCD19-aCD33 would coat not only the CD19- and 
CD33-positive target cells such as leukemic cells with MLL pheno-
type but also any existing or newly emerging clones that lost one of 
the antigens (Figure 1). ULBP2-aCD19 and ULBP2-aCD33, the 
bispecific immunoligands either targeting CD19 or CD33, would 
fail in this regard. To mimic the antigen loss variants of BV173 cell 
line, CD19 and/or CD33 antigens were preblocked using molar 
excess of CD19- or CD33-specific scFv moieties (aCD19scFv or 
aCD33scFv) that lacked an ULBP2 ligand. This has previously 
shown to completely abolish binding of the immunoligands 
and subsequent killing of target cells in an antigen-specific 
manner (47). As shown in Figure  2, when both antigens were 
accessible on BV173 (CD19+CD33+), all three immunoligands 
significantly enhanced the NK-cell-dependent killing of BV173 
cells, albeit depending upon the expression level of the respective 
antigen. Of note, the surface expression of CD19 on the BV173 
is several fold higher compared to CD33 (47, 49). When CD19 
antigen was blocked (CD19blockCD33+) by preincubation with 
aCD19scFv construct, BV173 killing induced by ULBP2-aCD19 
was completely abolished while ULBP2-aCD33 and ULBP2-
aCD19-aCD33 retained their toxic effects. Similarly, CD33 
blocking on BV173 (CD19+CD33block) by aCD33scFv could 
abolish killing by ULBP2-aCD33 but not by ULBP2-aCD19 
and the triplebody. Only, simultaneous blocking of both CD19 
and CD33 antigens could abolish the killing induced by the 
dual-targeting triplebody ULBP2-aCD19-aCD33. This prototype 
immunoligand can also be modified to target a different com-
bination of antigens such as CD19 and CD20 in case of CLL. 
Theoretically, it is also possible that tumor clones that have lost 
the expression of both antigens preexist within the heterogeneous 
tumor population and can be further selected even after dual-
targeting approach. Moreover, this is also relevant in the context 
of antigen loss following targeted therapy as simultaneous loss 
of CD19 and CD20 antigens has been noted following rituximab 
therapy (34). Therefore, clinical success of the dual-targeting 
strategy will require careful selection of the tumor antigen pair 
and combination therapies should be considered in the case of 
double antigen loss.
Although this study focused on NK cell-dependent effects, 
NKG2D is also a shared activating receptor on γ/δ T cells and 
a coactivating receptor on CD8+ T cells. NKG2D-dependent 
antitumor effector functions of both of these T cell populations 
have been reported by us and others. Therefore, we believe that 
NKG2D targeting would facilitate a more dynamic immune 
FiGUre 2 | continued
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FiGUre 2 | continued 
A dual targeting triplebody ULBP2-acD19-acD33 mediates NK cell-dependent killing of antigen loss variants. (A) NK cells were purified from healthy 
donor by negative selection and were primed by IL2 (200 U/ml) + IL15 (10 ng/ml) cytokines for 15–18 h (overnight). Next day, primed NK cells were incubated with 
DiR dye-labeled BV173 cells at indicated effector to target (E:T) ratio for 3 h. The incubation was continued either alone (No construct) or in the presence of 100 nM 
of immunoligand (U-19: ULBP2-aCD19, U-33: ULBP2-aCD33, U-19-33: ULBP2-aCD19-aCD33). After incubation, 7-AAD was added and 7-AAD-positive cells 
within DiR-positive gate indicated dead BV173 cells. One representative toxicity assay is shown. (B) Cumulative analysis of four independent toxicity assays at 2.5:1 
(E:T) ratio (N = 4; each N represents an independent healthy NK cell donor). Error bars indicate SEM and statistical analysis by one-way ANOVA.
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reaction involving both, innate and adaptive arms. In human 
and mice, chronic stimulation of NKG2D receptor by membrane 
bound ligands leads to the reduced surface expression of NKG2D 
receptor (50, 51). However, ULBP2 is not as effective as MICA in 
causing downmodulation of NKG2D receptor (51), and we do 
not anticipate that the recombinant protein will be retained in the 
body fluids for a relevant period to cause significant downmodu-
lation of NKG2D receptor.
Taken together, incorporating additional tumor specificity 
to the current mono-targeting T and NK cell-based therapies 
appears to be a promising approach to prevent or treat antigen loss 
relapse. Their ultimate clinical benefits may be more accurately 
predicted by addressing whether there are any additional adverse 
effects that are particularly associated with dual specificities.
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